Vinorelbine Tartrate 10mg / ml injection
Ferron Par Pharmaceuticals
Ingredients in every ml
|Vinorelbine Tartrate||10 mg|
Each package contains
|ATC Level 1||L - Antineoplastic and immunomodulating agents|
|ATC Level 2||L01 - Antineoplastic Agents|
|ATC Level 3||L01C - Plant Alkaloids and Other Natural Products; Antineoplastic Drugs|
Strictly by intravenous administration after appropriate dilution. The use of intrathecal route is contraindicated. It is recommended to infuse vinorelbine over 6-10 minutes after dilution in 20-50 ml of 0.9% NaCl Injection (normal saline solution) or 5% dextrose solution. Administration should always be followed with at least 250 ml of an isotonic solution infusion to flush the vein.
— In monotherapy:
The usual dose given is 25-30 mg/m² once weekly.
— In combination chemotherapy:
The dose may be the same while the frequency of administration reduced, i.e.: day 1 and 5 every 3 weeks or day 1 and 8 every 3 weeks according to treatment protocol.
PATIENTS WITH RENAL INSUFFICIENCY
No dose adjustments are required for renal insufficiency. If moderate or severe neurotoxicity develops, vinorelbine should be discontinued. The dosage should be adjusted according to hematologic toxicity or hepatic insufficiency, whichever results the lower dose.
Treatment of non-small cell lung cancer and advanced breast cancer in combination with standard chemotherapy.